BBA
PVLA

Baader Bank Aktiengesellschaft’s Palvella Therapeutics PVLA Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,131
Closed -$326K – 571
2025
Q4 		$326K Buy
+3,131
New +$267K 0.02% 354
2024
Q1 		– Sell
-254
Closed -$2.74K – 411
2023
Q4 		$2.74K Buy
+254
New +$4.65K ﹤0.01% 312
2023
Q3 		– Sell
-131
Closed -$1.35K – 486
2023
Q2 		$1.35K Buy
+131
New +$7.94K ﹤0.01% 399

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baader Bank Aktiengesellschaft's PVLA Position: Q1 2026 in Review

Baader Bank Aktiengesellschaft sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 3,131 shares — an estimated $326K sold.

Baader Bank Aktiengesellschaft first reported a position in PVLA in Q2 2023 and held it in 3 quarters. The position peaked at $326K in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Baader Bank Aktiengesellschaft reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 3,131 Palvella Therapeutics shares in Q1 2026, an estimated $326K.
  • Baader Bank Aktiengesellschaft first reported a position in Palvella Therapeutics in Q2 2023 and held it in 3 quarters.
  • Baader Bank Aktiengesellschaft's Palvella Therapeutics position peaked at $326K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q1 2026, filed 8 May 2026.